c‐Myc‐mediated epigenetic silencing of MicroRNA‐101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma
暂无分享,去创建一个
Jing Zhao | Tao Wang | K. Dou | Y. Nie | Xiang Zhang | A. Yang | Lei Wang | L. Jia | Rui Zhang | L. Yao | Jianming Yang | Si-jun Hu | Si-Yi Chen | Zhe Wang | Rui‐an Wang | Jun Zhao | D. Fan | Weihong Wen | Yan-ling Meng | Jian‐Dong Yang
[1] Kai Fu,et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. , 2012, Cancer cell.
[2] Hua-Chien Chen,et al. Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells , 2012, Nucleic acids research.
[3] I. Ng,et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis , 2012, Hepatology.
[4] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[5] M. Hung,et al. The role of EZH2 in tumour progression , 2011, British Journal of Cancer.
[6] A. Dinner,et al. Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2 , 2011, Nature Immunology.
[7] Qiang Yu,et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.
[8] T. Sakmar,et al. CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration* , 2011, The Journal of Biological Chemistry.
[9] H. Pan,et al. Molecular mechanism of liver cancer. , 2011, Anti-cancer agents in medicinal chemistry.
[10] Y. Hu,et al. Embryonic ectoderm development protein is regulated by microRNAs in human neural tube defects. , 2011, American journal of obstetrics and gynecology.
[11] O. Fainaru,et al. Immature myeloid cells accumulate in mouse placenta and promote angiogenesis. , 2011, American journal of obstetrics and gynecology.
[12] A. Chase,et al. Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.
[13] Y. Zeng,et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies , 2011, Gut.
[14] Li Lin,et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.
[15] D. Reinberg,et al. The Polycomb complex PRC2 and its mark in life , 2011, Nature.
[16] Shu Liu,et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. , 2010, Genes & development.
[17] X. Wang,et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer , 2010, Proceedings of the National Academy of Sciences.
[18] C. Croce,et al. MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Kevin Struhl,et al. An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation , 2009, Cell.
[20] Michael R. Green,et al. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. , 2009, Molecular cell.
[21] E. Hahn,et al. Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. , 2009, International journal of oncology.
[22] Yi Tie,et al. MicroRNA‐101 regulates expression of the v‐fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma , 2009, Hepatology.
[23] S. Thorgeirsson,et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. , 2009, Cancer research.
[24] Jian-Rong Yang,et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.
[25] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[26] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[27] J. Pollack,et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.
[28] C. Croce,et al. MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.
[29] K. Helin,et al. Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor , 2008, Molecular and Cellular Biology.
[30] D. Gold,et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.
[31] W. Tansey,et al. Myc-mediated transcriptional repression by recruitment of histone deacetylase. , 2008, Cancer research.
[32] R. Eils,et al. Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.
[33] J. Sung,et al. Lentivirus‐mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down‐regulation of stathmin , 2007, Hepatology.
[34] T. Golub,et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.
[35] Qiang Yu,et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.
[36] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.
[37] N. Fusenig,et al. Critical role for NF‐κB‐induced JunB in VEGF regulation and tumor angiogenesis , 2007 .
[38] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[39] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[40] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[42] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[43] Christopher H. Contag,et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.
[44] Xiaofei Li,et al. TRANSFORMATION , 2001, Human Rights: Universality and Diversity.
[45] J. Strahler,et al. Involvement of OP18 in cell proliferation. , 1991, Biochemical and biophysical research communications.
[46] D. Spandidos,et al. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. , 1989, Anticancer research.
[47] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[48] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[49] N. Fusenig,et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. , 2007, The EMBO journal.